Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Guardant Health

    • Home
    • Guardant Health
Company Deals

Guardant Health and Boehringer Ingelheim Join Forces to Develop Guardant360 CDx for Zongertinib Companion Diagnostic

Fineline Cube Dec 20, 2024

US-based precision oncology specialist Guardant Health, Inc. (NASDAQ: GH) has entered into an agreement with...

Company Deals

AnHeart Therapeutics Partners with Guardant Health for Taletrectinib Diagnostics

Fineline Cube Feb 6, 2023

Sino-US biopharma AnHeart Therapeutics and US precision oncology firm Guardant Health Inc. (NASDAQ: GH) have...

Company Deals

Adicon Holdings and Guardant Health Partner on Genomic Profiling in China

Fineline Cube Jul 7, 2022

China-based Adicon Holdings Limited announced a strategic partnership with U.S. firm Guardant Health, Inc. (NASDAQ:...

Recent updates

  • IVD Medical Launches Nipah Virus Detection Kit with AI Early Warning Platform
  • Betta Pharmaceuticals’ BPI-572270 RAS Inhibitor Gets NMPA Nod for Solid Tumor Trials
  • Nanjing Leads Biolabs Secures FDA Fast Track for LBL-034 in Multiple Myeloma
  • NMPA Suspends Two Indian Pharma APIs Over GMP Violations
  • Zhaoke Ophthalmology Expands BRIMOCHOL PF Presbyopia Distribution to Singapore and Vietnam
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals Medical Device

IVD Medical Launches Nipah Virus Detection Kit with AI Early Warning Platform

Company Drug

Betta Pharmaceuticals’ BPI-572270 RAS Inhibitor Gets NMPA Nod for Solid Tumor Trials

Company Drug

Nanjing Leads Biolabs Secures FDA Fast Track for LBL-034 in Multiple Myeloma

Policy / Regulatory

NMPA Suspends Two Indian Pharma APIs Over GMP Violations

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.